Latest Breaking News On - மூலோபாய இணைந்து - Page 5 : comparemela.com

Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update -U.S. Food and Drug Administration (FDA) filing of a Biologics License Application (BLA) and Priority Review for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals; PDUFA goal date of July 2, 2021- News provided by Share this article Share this article RED BANK, N.J., Feb. 25, 2021 /PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the fourth quarter and full year ended December 31, 2020. 2020 was a pivotal year for Provention Bio and the type 1 diabetes (T1D) landscape, stated Ashleigh Palmer, CEO of Provention Bio. The FDA s filing of our BLA for teplizumab represents a momentous achievement for Provention Bio in our mission to potentially deliver the first disease-modifying T1D therapy, which may cat

Hong kongLori rosenSam martinRobert doodyAshleigh palmerProvention bioProvention bio incAgency priorityClinical research services turkuDrug administrationExchange commissionHangzhou zhongmei huadong pharmaceutical co ltdHuadong medicine co ltdPrnewswire provention bio incPriority reviewHuadong medicine